PT -期刊文章盟莎拉Llufriu Elisabetta帕加尼AU -玛丽亚罗卡盟盟Gianna卡拉Riccitelli AU -布鲁诺科伦坡盟Mariaemma Rodegher AU -安德里亚Falini盟-吉安卡洛Comi AU -马西莫菲利皮主持在多发性硬化症:TI - Hippocampal-related记忆网络结构连通性分析(P6.138) DP - 2015年4月06 TA -神经病学PG - P6.138 VI - 84 IP - 14补充4099 - //www.ez-admanager.com/content/84/14_Supplement/P6.138.short 4100 - //www.ez-admanager.com/content/8首页4/14_Supplement/P6.138.full所以Neurology2015 4月06;84 AB -目的:量化结构连通性hippocampal-related情景记忆网络的完整性及其与多发性硬化(MS)患者的记忆性能。背景:情景记忆通常是MS患者的影响。设计/方法:大脑弥散张量和3 d t1序列得到71 MS患者和50名健康志愿者(高压)。三十灰质区域(选择先验hippocampal-memory网络)的一部分被分割,作为种子进行概率tractography和为每个主题创建一个连接网络矩阵。全球、节点和边缘网络指标计算。口头和视觉空间记忆单词配对联结式学习评估与测试,短篇故事测试和Rey-Osterrieth复杂图延迟回忆任务。记忆认知损伤指数(MCII)也计算。RESULTS: Compared to HV, MS patients showed significantly decreased (p<0.01) strength, assortativity, transitivity, global efficiency and increased average path length of the whole network. Significant correlation was found between global efficiency and strength vs memory scores. The thalamus and parietal cortex were the nodes with highest betweenness centrality (BC) and strength of the network both in patients and HV. Several nodes showed increased BC and decreased strength in MS patients compared to HV (p<0.01). Thirty-nine/435 edges had decreased communicability, whereas 108/435 edges had decreased fiber count (p<0.01, FDR correction). The thalamus and amygdala had increased communicability with other nodes in MS patients vs HV. Performance at single cognitive tests correlated with node and edge properties. CONCLUSIONS: The hippocampus-related memory network is globally impaired in MS patients, even if it maintains a configuration in which the thalamus and parietal lobes show the highest strength and BC. The integrity of this network seems relevant for preserving memory functions. Partially supported by a grant from Fondazione Italiana Sclerosi Multipla (FISM 2012/R/8).Disclosure: Dr. Llufriu has received personal compensation for activities with Teva Neuroscience, Novartis, and EDM Serono as a speaker. Dr. Rocca has received personal compensation for activities with Novartis, Biogen Idec, and Serono, Inc. as a speaker. Dr. Pagani has nothing to disclose. Dr. Riccitelli has nothing to disclose. Dr. Colombo has nothing to disclose. Dr. Rodegher has nothing to disclose. Dr. Falini has nothing to disclose. Dr. Comi has received personal compensation for activities with Teva, Novartis, Genzyme, Merck Serono, Biogen Idec, Bayer, Actelion Pharmaceuticals, Almirall, and Serono. Cure PSP, Alzheimer's Drug Discovery Foundation, and the Jacques and Gloria GossweilerThursday, April 23 2015, 7:30 am-12:00 pm